The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Ezra E. W. Cohen
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
Masha Kocherginsky
No relevant relationships to disclose
Chao H Huang
Research Funding - Sanofi
Mark Agulnik
No relevant relationships to disclose
Bharat Bhushan Mittal
No relevant relationships to disclose
Furhan Yunus
No relevant relationships to disclose
Sandeep Samant
No relevant relationships to disclose
Bruce Brockstein
No relevant relationships to disclose
Luis E. Raez
Honoraria - Sanofi
Research Funding - Sanofi
Ranee Mehra
No relevant relationships to disclose
Priya Kumar
No relevant relationships to disclose
Frank G. Ondrey
No relevant relationships to disclose
Tanguy Y. Seiwert
No relevant relationships to disclose
Victoria Meucci Villaflor
No relevant relationships to disclose
Daniel J. Haraf
No relevant relationships to disclose
Everett E. Vokes
No relevant relationships to disclose